Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus NCI-H3122 (CVCL_5160)

[Text version]
Cell line name NCI-H3122
Synonyms H3122; H-3122; NCIH3122
Accession CVCL_5160
Resource Identification Initiative To cite this cell line use: NCI-H3122 (RRID:CVCL_5160)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: 48.5 hours (PubMed=29681454).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=18594010; DOI=10.1101/2022.06.08.495301; DepMap=ACH-000337).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North1.36
East Asian, South0
South Asian1.48
European, North65.9
European, South31.26
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_4Y37 (NCI-H3122-CHR-A1)CVCL_AY53 (NCI-H3122-CR1)
Sex of cell Male
Age at sampling 54Y
Category Cancer cell line
STR profile Source(s): CLS=300484; Cosmic-CLP=1240190; PubMed=20679594

Markers:
AmelogeninX
CSF1PO11,12
D5S81811,12
D7S8208,12
D8S117913,15
D13S31710,12
D16S53911,12
D18S5113,16
FGA18,21
Penta D10,13
Penta E12
TH017,9.3
TPOX10
vWA16

Run an STR similarity search on this cell line
Publications

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=12759538; DOI=10.1159/000070299
Fujishita T., Loda M., Turner R.E., Gentler M., Kashii T., Breathnach O.S., Johnson B.E.
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel.
Oncology 64:399-406(2003)

PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168
Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Clin. Cancer Res. 14:4275-4283(2008)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0
Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L., Chung D.H., Heo D.S.
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
J. Thorac. Oncol. 8:415-422(2013)

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846
Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov. 4:662-673(2014)

PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003
Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C., Daub H.
Comparative proteome analysis across non-small cell lung cancer cell lines.
J. Proteomics 130:1-10(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31803961; DOI=10.1002/jcb.29564
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)

DOI=10.1101/2022.06.08.495301
Licciardello M.P., Zhang C., Le A.T., Doebele R.C., Clarke P.A., Workman P.
Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors.
bioRxiv 2022:06.08.495301-06.08.495301(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 300484
NCI-DTP; NCI-H3122
Cell line databases/resources CLO; CLO_0037033
cancercelllines; CVCL_5160
Cell_Model_Passport; SIDM00137
Cosmic-CLP; 1240190
DepMap; ACH-000337
IGRhCellID; H3122GEO
LINCS_LDP; LCL-1675
Biological sample resources BioSample; SAMN10989614
CRISP screens repositories BioGRID_ORCS_Cell_line; 962
Chemistry resources ChEMBL-Cells; CHEMBL4295436
ChEMBL-Targets; CHEMBL4296475
GDSC; 1240190
PharmacoDB; NCIH3122_1104_2019
PubChem_Cell_line; CVCL_5160
Encyclopedic resources Wikidata; Q54908028
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM171874
GEO; GSM171875
GEO; GSM253349
GEO; GSM434307
GEO; GSM794370
GEO; GSM1374739
GEO; GSM1374740
GEO; GSM1670238
Polymorphism and mutation databases Cosmic; 755472
Cosmic; 914951
Cosmic; 1146912
Cosmic; 2245571
Progenetix; CVCL_5160
Proteomic databases PRIDE; PXD002556
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000082
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number35